Expression of ubiquitin‑conjugating enzyme E2T in colorectal cancers and clinical implications

Wu,Xiangtian; Liu,Gang; Liu,Ruiting; He,Jing; Wang,Guorong; Zhang,Haibao; Liu,Tianjie; Bai,Jirong; Cheng,Ning; Qiu,Jian

doi:10.3892/ol.2020.12138

Expression of ubiquitin‑conjugating enzyme E2T in colorectal cancers and clinical implications

Authors:
- Xiangtian Wu
- Gang Liu
- Ruiting Liu
- Jing He
- Guorong Wang
- Haibao Zhang
- Tianjie Liu
- Jirong Bai
- Ning Cheng
- Jian Qiu
View Affiliations

Affiliations: Department of General Surgery, Shaanxi Provincial People's Hospital, Xi'an, Shaanxi 710061, P.R. China, Department of Emergency Surgery, East Hospital, Tongji University, Shanghai 200120, P.R. China, Department of Pathology, University of Texas Medical Branch, Galveston, TX 77555, USA, Department of Urology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710000, P.R. China, Department of Pathology, University of Nebraska Medical Center, Omaha, NE 68198, USA
Published online on: September 21, 2020 https://doi.org/10.3892/ol.2020.12138
Article Number: 275
Copyright: © Wu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Ubiquitin‑conjugating enzyme E2T (UBE2T) plays a significant role in carcinogenesis. Previous studies have demonstrated that UBE2T promotes the development and progression of numerous types of cancer. However, the association between UBE2T expression and colorectal cancer (CRC) remains unclear. In the present study, UBE2T protein expression was examined in the tissues of patients with CRC via immunohistochemistry. In addition, UBE2T expression data and corresponding clinical information were obtained from The Cancer Genome Atlas (TCGA). In the clinical samples, the associations between UBE2T expression and clinicopathological factors were evaluated by the χ² or Fisher's exact tests. In TCGA data, associations between UBE2T expression and clinical characteristics were evaluated using a logistic regression model. Overall survival was analyzed using Kaplan‑Meier and Cox regression analyses. Reverse transcription‑quantitative PCR (RT‑qPCR) and western blotting assays were used to examine UBE2T expression in normal and CRC cell lines. Gene set enrichment analysis (GSEA) was performed on the dataset from TCGA. UBE2T protein was highly expressed in the cytoplasm of tumor cells in 29/50 clinical samples, whereas in the adjacent normal tissues, it was only highly expressed in 2/50 samples. Furthermore, UBE2T expression was associated with the N classification (P<0.001), clinical TNM stage (P<0.001) and histological grade of tumors (P=0.010). Survival analysis showed an association between high UBE2T expression and poor survival rate in patients with CRC (P=0.002). Cox regression analysis also revealed that UBE2T expression was an independent prognostic factor for these patients (P=0.006). RT‑qPCR and western blotting showed that UBE2T was expressed in CRC cell lines at higher levels than that in a normal colon cell line. Analysis of TCGA data revealed that UBE2T was highly expressed in tumor samples compared with normal samples, but was not associated with prognosis. GSEA showed that high expression of UBE2T was associated with the Kyoto Encyclopedia of Genes and Genomes pathways ‘cell cycle’, ‘oxidative phosphorylation’, ‘DNA replication’, ‘p53 signaling pathway’, ‘ubiquitin mediated proteolysis’ and ‘pentose phosphate pathway’. These results indicate that UBE2T may play an important role in the progression of CRC and serve as a potential prognostic factor during the treatment of cancer.

View Figures

View References

1	Siegel RL, Miller KD, Goding SA, Fedewa SA, Butterly LF, Anderson JC, Cercek A, Smith RA and Jemal A: Colorectal cancer statistics, 2020. CA Cancer J Clin. 70:145–164. 2020. View Article : Google Scholar : PubMed/NCBI
2	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI
3	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
4	Custodio A and Feliu J: Prognostic and predictive biomarkers for epidermal growth factor receptor-targeted therapy in colorectal cancer: Beyond KRAS mutations. Crit Rev Oncol Hematol. 85:45–81. 2013. View Article : Google Scholar : PubMed/NCBI
5	Lim KH, Song MH and Baek KH: Decision for cell fate: Deubiquitinating enzymes in cell cycle checkpoint. Cell Mol Life Sci. 73:1439–1455. 2016. View Article : Google Scholar : PubMed/NCBI
6	Zhou MJ, Chen FZ and Chen HC: Ubiquitination involved enzymes and cancer. Med Oncol. 31:932014. View Article : Google Scholar : PubMed/NCBI
7	Rickman KA, Lach FP, Abhyankar A, Donovan FX, Sanborn EM, Kennedy JA, Sougnez C, Gabriel SB, Elemento O, Chandrasekharappa SC, et al: Deficiency of UBE2T, the E2 ubiquitin ligase necessary for FANCD2 and FANCI ubiquitination, causes FA-T subtype of fanconi anemia. Cell Rep. 12:35–41. 2015. View Article : Google Scholar : PubMed/NCBI
8	Alpi A, Langevin F, Mosedale G, Machida YJ, Dutta A and Patel KJ: UBE2T, the Fanconi anemia core complex, and FANCD2 are recruited independently to chromatin: A basis for the regulation of FANCD2 monoubiquitination. Mol Cell Biol. 27:8421–8430. 2007. View Article : Google Scholar : PubMed/NCBI
9	Joenje H and Patel KJ: The emerging genetic and molecular basis of Fanconi anaemia. Nat Rev Genet. 2:446–457. 2001. View Article : Google Scholar : PubMed/NCBI
10	Weiser MR: AJCC 8th edition: Colorectal cancer. Ann Surg Oncol. 25:1454–1455. 2018. View Article : Google Scholar : PubMed/NCBI
11	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
12	Lee YT, Tan YJ and Oon CE: Molecular targeted therapy: Treating cancer with specificity. Eur J Pharmacol. 834:188–196. 2018. View Article : Google Scholar : PubMed/NCBI
13	Nikolaou S, Qiu S, Fiorentino F, Rasheed S, Tekkis P and Kontovounisios C: Systematic review of blood diagnostic markers in colorectal cancer. Tech Coloproctol. 22:481–498. 2018. View Article : Google Scholar : PubMed/NCBI
14	Bhatti I, Patel M, Dennison AR, Thomas MW and Garcea G: Utility of postoperative CEA for surveillance of recurrence after resection of primary colorectal cancer. Int J Surg. 16:123–128. 2015. View Article : Google Scholar : PubMed/NCBI
15	Tsilimigras DI, Ntanasis-Stathopoulos I, Bagante F, Moris D, Cloyd J, Spartalis E and Pawlik TM: Clinical significance and prognostic relevance of KRAS, BRAF, PI3K and TP53 genetic mutation analysis for resectable and unresectable colorectal liver metastases: A systematic review of the current evidence. Surg Oncol. 27:280–288. 2018. View Article : Google Scholar : PubMed/NCBI
16	Raskov H, Pommergaard HC, Burcharth J and Rosenberg J: Colorectal carcinogenesis-update and perspectives. World J Gastroenterol. 20:18151–18164. 2014. View Article : Google Scholar : PubMed/NCBI
17	Bassermann F, Eichner R and Pagano M: The ubiquitin proteasome system-implications for cell cycle control and the targeted treatment of cancer. Biochim Biophys Acta. 1843:150–162. 2014. View Article : Google Scholar : PubMed/NCBI
18	Teixeira LK and Reed SI: Ubiquitin ligases and cell cycle control. Annu Rev Biochem. 82:387–414. 2013. View Article : Google Scholar : PubMed/NCBI
19	Alpi AF, Chaugule V and Walden H: Mechanism and disease association of E2-conjugating enzymes: Lessons from UBE2T and UBE2L3. Biochem J. 473:3401–3419. 2016. View Article : Google Scholar : PubMed/NCBI
20	Hira A, Yoshida K, Sato K, Okuno Y, Shiraishi Y, Chiba K, Tanaka H, Miyano S, Shimamoto A, Tahara H, et al: Mutations in the gene encoding the E2 conjugating enzyme UBE2T cause Fanconi anemia. Am J Hum Genet. 96:1001–1007. 2015. View Article : Google Scholar : PubMed/NCBI
21	Longerich S, San Filippo J, Liu D and Sung P: FANCI binds branched DNA and is monoubiquitinated by UBE2T-FANCL. J Biol Chem. 284:23182–23186. 2009. View Article : Google Scholar : PubMed/NCBI
22	Kelsall IR, Langenick J, MacKay C, Patel KJ and Alpi AF: The Fanconi anaemia components UBE2T and FANCM are functionally linked to nucleotide excision repair. PLoS One. 7:e369702012. View Article : Google Scholar : PubMed/NCBI
23	Ueki T, Park JH, Nishidate T, Kijima K, Hirata K, Nakamura Y and Katagiri T: Ubiquitination and downregulation of BRCA1 by ubiquitin-conjugating enzyme E2T overexpression in human breast cancer cells. Cancer Res. 69:8752–8760. 2009. View Article : Google Scholar : PubMed/NCBI
24	Gong YQ, Peng D, Ning XH, Yang XY, Li XS, Zhou LQ and Guo YL: UBE2T silencing suppresses proliferation and induces cell cycle arrest and apoptosis in bladder cancer cells. Oncol Lett. 12:4485–4492. 2016. View Article : Google Scholar : PubMed/NCBI
25	Hao J, Xu A, Xie X, Hao J, Tian T, Gao S, Xiao X and He D: Elevated expression of UBE2T in lung cancer tumors and cell lines. Tumour Biol. 29:195–203. 2008. View Article : Google Scholar : PubMed/NCBI
26	Yu H, Xiang P, Pan Q, Huang Y, Xie N and Zhu W: Ubiquitin-conjugating enzyme E2T is an independent prognostic factor and promotes gastric cancer progression. Tumour Biol. 37:11723–11732. 2016. View Article : Google Scholar : PubMed/NCBI
27	Hu W, Xiao L, Cao C, Hua S and Wu D: UBE2T promotes nasopharyngeal carcinoma cell proliferation, invasion, and metastasis by activating the AKT/GSK3β/β-catenin pathway. Oncotarget. 7:15161–15172. 2016. View Article : Google Scholar : PubMed/NCBI
28	Wu M, Li X, Huang W, Chen Y, Wang B and Liu X: Ubiquitin-conjugating enzyme E2T(UBE2T) promotes colorectal cancer progression by facilitating ubiquitination and degradation of p53. Clin Res Hepatol Gastroenterol. Jul 29–2020.(Online ahead of print). View Article : Google Scholar
29	Evan GI and Vousden KH: Proliferation, cell cycle and apoptosis in cancer. Nature. 411:342–348. 2001. View Article : Google Scholar : PubMed/NCBI
30	Kastan MB and Bartek J: Cell-cycle checkpoints and cancer. Nature. 432:316–323. 2004. View Article : Google Scholar : PubMed/NCBI
31	Sica V, Bravo-San Pedro JM, Stoll G and Kroemer G: Oxidative phosphorylation as a potential therapeutic target for cancer therapy. Int J Cancer. 146:10–17. 2020. View Article : Google Scholar : PubMed/NCBI
32	Slattery ML, Mullany LE, Wolff RK, Sakoda LC, Samowitz WS and Herrick JS: The p53-signaling pathway and colorectal cancer: Interactions between downstream p53 target genes and miRNAs. Genomics. 111:762–771. 2019. View Article : Google Scholar : PubMed/NCBI
33	Bashir T and Pagano M: Aberrant ubiquitin-mediated proteolysis of cell cycle regulatory proteins and oncogenesis. Adv Cancer Res. 88:101–144. 2003. View Article : Google Scholar : PubMed/NCBI
34	Patra KC and Hay N: The pentose phosphate pathway and cancer. Trends Biochem Sci. 39:347–354. 2014. View Article : Google Scholar : PubMed/NCBI
35	Mamrak NE, Shimamura A and Howlett NG: Recent discoveries in the molecular pathogenesis of the inherited bone marrow failure syndrome Fanconi anemia. Blood Rev. 31:93–99. 2017. View Article : Google Scholar : PubMed/NCBI